Drug Discovery World article quoting Max Baumann, Partner at Treehill
๐ ๐ง๐ต๐ฒ “๐๐ฟ๐ฒ๐ฎ๐ ๐ ๐ถ๐ด๐ฟ๐ฎ๐๐ถ๐ผ๐ป” ๐ถ๐ ๐ฟ๐ฒ๐ฎ๐น โ ๐ฎ๐ป๐ฑ ๐ถ๐’๐ ๐ฟ๐ฒ๐๐ต๐ฎ๐ฝ๐ถ๐ป๐ด ๐ด๐น๐ผ๐ฏ๐ฎ๐น ๐ฏ๐ถ๐ผ๐๐ฒ๐ฐ๐ต ๐ก
An extraordinary 75% of US scientists are considering leaving America due to policy uncertainty and NIH funding cuts. European universities are responding with new grant programs, creating an unprecedented “brain drain” from the US to Europe.
As we told DDW: “๐ฃ๐ฟ๐ถ๐๐ฎ๐๐ฒ ๐ถ๐ป๐๐ฒ๐๐๐บ๐ฒ๐ป๐ ๐ฟ๐ฒ๐บ๐ฎ๐ถ๐ป๐ ๐ต๐ถ๐ด๐ต๐น๐ ๐๐ฒ๐น๐ฒ๐ฐ๐๐ถ๐๐ฒ, ๐ฐ๐ฟ๐ฒ๐ฎ๐๐ถ๐ป๐ด ๐ฏ๐ผ๐๐๐น๐ฒ๐ป๐ฒ๐ฐ๐ธ๐ ๐ฎ๐ป๐ฑ ๐น๐ฒ๐ฎ๐๐ถ๐ป๐ด ๐ฐ๐ผ๐บ๐ฝ๐ฎ๐ป๐ถ๐ฒ๐ ๐๐๐ฟ๐ฎ๐ป๐ฑ๐ฒ๐ฑ.”
๐ง๐ต๐ฒ ๐ถ๐บ๐ฝ๐ฎ๐ฐ๐ ๐ถ๐ ๐ฎ๐น๐ฟ๐ฒ๐ฎ๐ฑ๐ ๐๐ถ๐๐ถ๐ฏ๐น๐ฒ:
โ๏ธ Big pharma rushing to invest in US operations ($50B from Roche, $55B from J&J) to avoid tariffs
โ๏ธ European biotech saw 25.4% funding decline while APAC grew 55.3%
โ๏ธ Switzerland still attracted CHF 2.5 billion despite global headwinds
โ๏ธ EU launching โฌ500M “super grants” package to retain and attract talent
But here’s what most aren’t seeing: this disruption creates unprecedented restructuring opportunities for companies positioned to navigate the capital geography shift.
๐ง๐ต๐ฒ ๐พ๐๐ฒ๐๐๐ถ๐ผ๐ป ๐ถ๐๐ป’๐ ๐๐ต๐ฒ๐๐ต๐ฒ๐ฟ ๐๐๐ฟ๐ผ๐ฝ๐ฒ ๐ฐ๐ฎ๐ป ๐๐ฎ๐ธ๐ฒ ๐๐ต๐ฒ ๐น๐ฒ๐ฎ๐ฑ โ it’s how companies will position themselves to capture value from this massive realignment of global biotech infrastructure.
โ How is your organization adapting to this new geopolitical reality? Are you seeing opportunities emerge from the constraints?
๐ช What strategic moves are you considering beyond just “waiting for stability”?
๐ Treehill Partners โ helping biopharma companies navigate complex market transitions and optimize strategies for both regulatory success and commercial value creation across changing global landscapes.
Read the full article on:
https://www.ddw-online.com/can-europe-take-the-lead-on-biotech-35716-202507/